Free Trial

Inhibrx Q2 2024 Earnings Report

Inhibrx logo
$14.12 -0.20 (-1.40%)
As of 03/28/2025 04:00 PM Eastern

Inhibrx EPS Results

Actual EPS
$125.48
Consensus EPS
-$3.60
Beat/Miss
Beat by +$129.08
One Year Ago EPS
N/A

Inhibrx Revenue Results

Actual Revenue
$0.10 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Inhibrx Announcement Details

Quarter
Q2 2024
Time
TAS

Conference Call Resources

Remove Ads

Inhibrx Earnings Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Inhibrx Biosciences Inc (INBX) Gets a Hold from JMP Securities
See More Inhibrx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Inhibrx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inhibrx and other key companies, straight to your email.

About Inhibrx

Inhibrx (NASDAQ:INBX), a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

View Inhibrx Profile

More Earnings Resources from MarketBeat